SCHEMBL6936873

SCHEMBL6936873

CC(=O)OC(C(=O)C1=C(C(C)C)[CH]C(C(C)C)C=C1)c1c(C(C)C)cc(C(C)C)cc1C(C)C

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.31
FABP4 P15090 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6936609 0.73 SOAT2 (0.35) FABP3FABP4
SCHEMBL8706654 0.71 FABP3 (0.33) FABP3FABP4
SCHEMBL8495041 0.71 FABP3 (0.49) FABP3FABP4
SCHEMBL7207646 0.68 ALDH1A1 (0.38) FABP3FABP4
SCHEMBL7207643 0.64 FABP3 (0.33) FABP3FABP4
SCHEMBL7206855 0.61 SOAT2 (0.36) FABP3FABP4
SCHEMBL6941985 0.58 SOAT2 (0.34) FABP3FABP4
SCHEMBL8176820 0.57 FABP3 (0.52) FABP3FABP4
SCHEMBL27601383 0.56 ALDH1A1 (0.43)
SCHEMBL16710393 0.55 KDM4E (0.45) FABP3FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2003513909-A 2003-04-15 JP claimed
EP-1229907-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-08-14 EP claimed
WO-2001034127-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-05-17 WO claimed
EP-1229907-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-08-14 EP disclosed
WO-2001034127-A1 PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-05-17 WO disclosed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed